ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

New Research From Inovalon and Harvard University Finds Medicare Advantage Beneficiaries Have Superior Quality Outcomes Relative to Traditional Medicare

Data Shows Lack of Care Management and Coordination of Services in Fee-for-Service Medicare Leads to Lower Quality of Care and Worse Outcomes

  • Medicare Advantage (MA) has 70% fewer readmissions than Fee-for-Service (FFS) Medicare
  • MA has 24% fewer preventable hospitalizations than FFS, primarily driven by 59% fewer preventable acute hospitalizations
  • MA has 21% lower rates of high-risk medication use, while overall medication use is in line with FFS

BOWIE, Md., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Inovalon, a leading provider of cloud-based software solutions empowering data-driven healthcare, and Harvard Medical School researchers today released new research that shows Medicare Advantage (MA) delivers superior quality and health outcomes relative to traditional Fee-for-Service (FFS) Medicare. Using Inovalon’s unique data assets and analytics to look at a broad range of quality measures across care settings, the research shows that patients enrolling in MA realize substantially reduced rates of chronic and acute care complications. The findings are the latest to be released from the first-of-its-kind research collaboration with Inovalon and Harvard Medical school and builds on earlier research showing substantial inpatient utilization reductions under MA.

MA now covers more than half of Medicare beneficiaries, including a disproportionately large share of socioeconomically disadvantaged patient populations. Despite the growing popularity of MA plans, limited information is available on how care quality differs under MA and FFS coverage. The study, “Quality Outcomes Under Medicare Advantage versus Medicare Fee-for-Service,” found consistently better quality outcomes under MA than FFS, including 70% fewer readmissions under MA. MA also had 24% fewer preventable hospitalizations, with 59% fewer preventable acute hospitalizations. In addition, the study found 21% lower rates of inappropriate high-risk medication use under MA while overall medication use was similar in MA and FFS.

“The study provides strong evidence that care management and coordination are key to better outcomes,” said Boris Vabson, PhD, health economist at Harvard Medical School and co-lead researcher on the project. “While recent reforms such as the introduction of Accountable Care Organizations (ACOs) have attempted to improve Medicare care management, our research shows additional steps are needed to improve care coordination and quality of care under Fee-for-Service Medicare.”

To quantify the impact of MA vs. FFS on key quality outcomes, the research team analyzed quality measures for a large, nationally representative population over a two-year timespan as beneficiaries transitioned from commercial insurance to MA or FFS coverage, while accounting for pre-existing differences prior to Medicare enrollment. This unique study was made possible through the use of data from Inovalon’s Medical Outcomes Research for Effectiveness and Economics (MORE2) Registry®, the nation’s largest primary source healthcare dataset covering 100% of public Medicare lives and 30% of all private insured lives.

“We believe this data can help health plans identify opportunities for quality improvement, especially for those in our health system who have been historically underserved and are at higher risk of needing complex care,” said Christie Teigland, PhD, Vice President of Research Science and Advanced Analytics at Inovalon and co-lead researcher on the project. “Under the new CMS Health Equity Index framework, it will be imperative for health plans to address socioeconomic disparities to improve 5-Star ratings and qualify for bonus payments. Our research gives them the insights they need to maximize financial incentives and, most importantly, promote health equity and deliver better health outcomes.”

Future research will look at specific, actionable opportunities for improving care quality and outcomes from a policy and plan design perspective.

To download the whitepaper and learn more about the research, please visit: Harvard & Inovalon Medicare Research Collaboration.

About Inovalon
        
Inovalon is a leading provider of cloud-based software solutions empowering data-driven healthcare. The Inovalon ONE® Platform brings together national-scale connectivity, real-time primary source data access, and advanced analytics into a sophisticated cloud-based platform empowering improved outcomes and economics across the healthcare ecosystem. The company’s analytics and capabilities are used by more than 20,000 customers and are informed by the primary source data of more than 79 billion medical events across one million physicians, 654,000 clinical settings, and 375 million unique patients. For more information, visit www.inovalon.com.

Contact:        

Nick Panayi

Chief Marketing Officer, Inovalon

Nick.Panayi@inovalon.com        


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.